Ser43

Site Information
GtPLsPGsLRsAAHs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3208731
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 )
Disease tissue studied:	breast cancer ( 4 , 11 ) , breast cancer, triple negative ( 4 ) , cervical cancer ( 15 ) , cervical adenocarcinoma ( 15 ) , leukemia ( 12 , 17 , 18 ) , acute myelogenous leukemia ( 12 , 17 , 18 ) , lung cancer ( 2 , 5 , 6 , 7 , 11 ) , non-small cell lung cancer ( 5 , 6 , 11 ) , non-small cell lung adenocarcinoma ( 2 , 5 , 6 , 7 ) , non-small cell large cell lung carcinoma ( 5 , 6 )
Relevant cell line - cell type - tissue:	bone marrow ( 17 , 18 ) , breast ( 4 ) , BT-20 (breast cell) ( 11 ) , BT-549 (breast cell) ( 11 ) , H2009 (pulmonary) ( 11 ) , H2077 (pulmonary) ( 11 ) , H2887 (pulmonary) ( 11 ) , H322M (pulmonary) ( 11 ) , HCC1359 (pulmonary) ( 11 ) , HCC1937 (breast cell) ( 11 ) , HCC2279 (pulmonary) ( 11 ) , HCC366 (pulmonary) ( 11 ) , HCC4006 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 6 , 11 ) , HCC827 (pulmonary) ( 11 ) , HeLa (cervical) ( 3 , 10 , 13 , 16 , 19 ) , HeLa S3 (cervical) ( 15 ) , HOP62 (pulmonary) ( 11 ) , HT-29 (intestinal) ( 20 , 21 ) , Jurkat (T lymphocyte) ( 8 , 14 ) , K562 (erythroid) ( 10 ) , KG-1 (myeloid) ( 12 ) , LCLC-103H (pulmonary) ( 11 ) , LOU-NH91 (squamous) ( 11 ) , lung ( 5 , 6 , 7 ) , MCF-7 (breast cell) ( 11 ) , MDA-MB-231 (breast cell) ( 11 ) , MDA-MB-468 (breast cell) ( 11 ) , NCI-H1299 (pulmonary) ( 5 ) , NCI-H1395 (pulmonary) ( 11 ) , NCI-H157 (pulmonary) ( 11 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H1734 (pulmonary) ( 5 ) , NCI-H1781 (pulmonary) ( 6 ) , NCI-H1944 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 11 ) , NCI-H2172 (pulmonary) ( 11 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H3122 (pulmonary) ( 6 ) , NCI-H322 (pulmonary) ( 11 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 5 , 11 ) , NCI-H520 (squamous) ( 11 ) , NCI-H661 (pulmonary) ( 6 ) , PC9 (pulmonary) ( 2 , 11 )

Upstream Regulation
Treatments:	nocodazole ( 15 )

References
1	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
2	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
8	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
9	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
10	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
11	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
12	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
13	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
14	Possemato A (2010) CST Curation Set: 10837; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
15	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
16	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
17	Gu T (2009) CST Curation Set: 7660; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
18	Gu T (2009) CST Curation Set: 7659; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
19	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
20	Moritz A (2005) CST Curation Set: 801; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
21	Moritz A (2005) CST Curation Set: 662; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info